RedHill Biopharma Ltd. (RDHL) stock

RDHLNasdaqPharmaceutical Preparations

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 27, 2026Score 0/30

$0.38−0.01 (-1.60%)

Close on Nov 13, 2026Market cap $1.91MP/E –Yield –

RedHill Biopharma statistics

63 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: –
Last ex-dividend date: No dividends
Fundamentals through: Jun 30, 2026
Share price as of: Nov 13, 2026

Valuation ratiosIndustry

Market Cap: $1.91M; $272.32M
Enterprise Value: -$3.25M; $146.23M
PS Ratio: 6.68; 3.66

Enterprise valuationIndustry

EV / Sales: -11.36; 2.57

Share statisticsIndustry

Shares Outstanding: 50.92B; 58M
Shares Change (YoY): 156.4%; 10.8%
Float: 48.67B; 49M
Shares Held by Insiders: 4.42%; 11.7%
Shares Held by Institutions: 0.00%; 56.4%

Short sellingIndustry

Short Interest: 61,151; –
Short Interest Change: -52.3%; -0.80%
Days to Cover: 1.00; 5.15

Stock price statisticsIndustry

52-Week High: $1.60; –
52-Week Low: $0.36; –
20-Day Moving Average: $0.42; –
50-Day Moving Average: $0.50; –
200-Day Moving Average: $0.76; –
Average True Range (14): $0.04; –
Price Change (1 Week): -12.4%; -1.15%
Price Change (1 Month): -24.9%; -4.87%
Price Change (3 Months): -35.9%; -21.0%
Price Change (6 Months): -63.6%; -20.6%
Price Change (YTD): -63.6%; -23.6%
Price Change (1 Year): -65.0%; -22.4%
Price Change (3 Years): -95.6%; -29.5%
Price Change (5 Years): -100.0%; -77.9%
Price Change (10 Years): -100.0%; -65.4%
Average Volume (10 Days): 69,461; –
Average Volume (20 Days): 104,158; –
Average Volume (90 Days): 1M; –
Relative Volume: 0.02; 0.70
Relative Strength Index (14): 37.2; 43.4
Volatility (1 Year): 91.2%; 80.1%
Beta (5 Years): 1.71; 1.07

MarginsIndustry

Operating Margin: -2776.9%; -38.7%
EBITDA Margin: -2776.9%; -27.7%
FCF Margin: -3376.2%; -9.56%

Returns on capitalIndustry

Return on Capital Employed (ROCE): -1113.9%; -37.9%

Financial positionIndustry

Current Ratio: 0.34; 3.30
Quick Ratio: 0.20; 2.39
Interest Coverage: -5.45; -6.35

GrowthIndustry

Revenue Growth (YoY): -96.4%; 6.82%
Revenue Growth (3Y CAGR): -83.3%; 2.25%
Revenue Growth (5Y CAGR): -66.2%; 6.41%

EfficiencyIndustry

Asset Turnover: 0.01; 0.40
Revenue Per Employee: $22.00K; $429.29K
Employee Count: 13; 74
WACC: 13.6%; 10.2%

Income statement (TTM)Industry

Revenue: $286.00K; $66.37M
Operating Income: -$7.94M; -$21.37M
EBITDA: -$7.94M; -$17.21M
EPS (Diluted): $0.00; -$0.76

Balance sheetIndustry

Cash & Short-Term Investments: $5.16M; $68.68M
Net Cash (Debt): $5.16M; $17.76M
Net Cash Per Share: $0.00; $0.80
Working Capital: -$16.99M; $79.99M

Cash flow (TTM)Industry

Operating Cash Flow: -$9.65M; -$12.38M
Capital Expenditures: -$5.00K; -$1.00M
Free Cash Flow: -$9.66M; -$18.21M
FCF Per Share: -$0.00; -$0.42

Dividends and yieldsIndustry

FCF Yield: -505.6%; -9.44%

Taxes and interestIndustry

Interest Expense: $1.46M; $2.90M

Scores and fair valueIndustry

Altman Z-Score: -24.06; 0.23

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	RDHL	S&P 500	Difference	RDHL per year	S&P 500 per year
1 month	-27.2%	-3.0%	−24.1 pts
3 months	-37.0%	-2.8%	−34.2 pts
Year to date	-63.6%	+11.5%	−75.1 pts
1 year	-65.0%	+13.5%	−78.4 pts
3 years	-95.2%	+77.7%	−172.9 pts	-63.6%	+21.1%
5 years	-100.0%	+72.6%	−172.6 pts	-85.0%	+11.5%
10 years	-100.0%	+308.2%	−408.2 pts	-64.6%	+15.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

0M RDHL shares were sold short on Oct 30, 2026, down 52.3% from the previous report. At recent volumes it would take 1.0 days to buy them back. Over the last 20 sessions, 27.4% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	61,151	-52.3%	132,590	1.0
Oct 15, 2026	128,328	-39.2%	1,568,822	1.0
Sep 30, 2026	211,200	-10.2%	134,664	1.6
Sep 15, 2026	235,258	+2710.1%	748,437	1.0
Aug 31, 2026	8,372	-43.1%	9,188,161	1.0
Aug 14, 2026	14,705	-50.9%	28,818	1.0
Jul 31, 2026	29,926	+49.7%	45,467	1.0
Jul 15, 2026	19,996	-35.8%	85,870	1.0
Jun 30, 2026	31,149	+119.7%	137,032	1.0
Jun 15, 2026	14,178	-36.4%	737,816	1.0
May 29, 2026	22,308	+2.3%	152,693	1.0
May 15, 2026	21,811	+14.4%	60,573	1.0

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in RedHill Biopharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on Aug 20, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is RDHL.

Compare: RDHL vs XTLB · RDHL vs CANF · RDHL vs LIPO · RDHL vs HIND · RDHL vs RLYB

Revenue growth-96.4% · median -35.6%

Operating margin-2776.9% · median -2853.6%

Company	Revenue	Growth
RLYB	$434.00K	-35.6%
LIPO	$389.78K	-19.4%
RDHL	$286.00K	-96.4%
HIND	$153.10K	-55.6%
XTLB	–	–
CANF	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Employees: 13
Held by institutions: 0.0%
Auditor: Kesselman & Kesselman
SEC CIK: 1553846

Advertisement
300 × 250

See a number that looks wrong?